Compare DCTH & SOPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DCTH | SOPH |
|---|---|---|
| Founded | 1988 | 2011 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 311.7M | 367.7M |
| IPO Year | 2015 | 2021 |
| Metric | DCTH | SOPH |
|---|---|---|
| Price | $10.81 | $4.83 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | ★ $22.00 | $7.50 |
| AVG Volume (30 Days) | ★ 270.4K | 89.3K |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 107.53 | N/A |
| EPS | ★ 0.07 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $24.54 | $23.09 |
| Revenue Next Year | $33.15 | $19.57 |
| P/E Ratio | $155.00 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.12 | $2.59 |
| 52 Week High | $18.23 | $5.70 |
| Indicator | DCTH | SOPH |
|---|---|---|
| Relative Strength Index (RSI) | 61.27 | 45.78 |
| Support Level | $10.50 | $4.55 |
| Resistance Level | $11.25 | $4.86 |
| Average True Range (ATR) | 0.37 | 0.25 |
| MACD | 0.03 | -0.02 |
| Stochastic Oscillator | 76.16 | 30.67 |
Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.